CoChat

Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations

Open access
Maramai, Samuele, Benchekroun, Mohamed, Gabr, Moustafa T., Yahiaoui, Samir · 2020 · BioMed Research International

The DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.

Abstract

Neurodegenerative diseases represent nowadays one of the major health problems. Despite the efforts made to unveil the mechanism leading to neurodegeneration, it is still not entirely clear what triggers this phenomenon and what allows its progression. Nevertheless, it is accepted that neurodegeneration is a consequence of several detrimental processes, such as protein aggregation, oxidative stress, and neuroinflammation, finally resulting in the loss of neuronal functions. Starting from these evidences, there has been a wide search for novel agents able to address more than a single event at the same time, the so‐called multitarget‐directed ligands (MTDLs). These compounds originated from the combination of different pharmacophoric elements which endowed them with the ability to interfere with different enzymatic and/or receptor systems, or to exert neuroprotective effects by modulating proteins and metal homeostasis. MTDLs have been the focus of the latest strategies to discover a new treatment for Alzheimer’s disease (AD), which is considered the most common form of dementia characterized by neurodegeneration and cognitive dysfunctions. This review is aimed at collecting the latest and most interesting target combinations for the treatment of AD, with a detailed discussion on new agents with favorable in vitro properties and on optimized structures that have already been assessed in vivo in animal models of dementia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2020/5120230

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 AChE inhibitors marketed for the treatment of AD (1-4) together with the NMDA receptor antagonist Memantine (5).
Figure 1 AChE inhibitors marketed for the treatment of AD (1-4) together with the NMDA receptor antagonist Memantine (5).CC BY · PubMed Central
Figure 2 Representative dopamine receptor agonists (6-9) and COMT inhibitors (10 and 11) for the treatment of PD.
Figure 2 Representative dopamine receptor agonists (6-9) and COMT inhibitors (10 and 11) for the treatment of PD.CC BY · PubMed Central
Figure 3 Compounds used in the treatment of hyperkinetic movement disorders related to HD (12) and used to slow down the progression of ALS (13 and 14).
Figure 3 Compounds used in the treatment of hyperkinetic movement disorders related to HD (12) and used to slow down the progression of ALS (13 and 14).CC BY · PubMed Central
Figure 4 Schematic representation of some recent and interesting combinations regarding ChEs and BACE-1 inhibitors and/or other targets involved in AD. Beside the dual action on the selected systems, most of the newly developed analogues have the potential to affect Aβ peptide aggregation along with oxidative stress and metal dyshomeostasis.
Figure 4 Schematic representation of some recent and interesting combinations regarding ChEs and BACE-1 inhibitors and/or other targets involved in AD. Beside the dual action on the selected systems, most of the newly developed analogues have the potential to affect Aβ peptide aggregation along with oxidative stress and metal dyshomeostasis.CC BY · PubMed Central
Figure 5 Structures of inspired- or rigid analogues of Donepezil as dual AChE and BACE-1 inhibitors. Highlighted are the main interactions with the two enzyme residues, mainly represented by H-bonds and hydrophobic interactions.
Figure 5 Structures of inspired- or rigid analogues of Donepezil as dual AChE and BACE-1 inhibitors. Highlighted are the main interactions with the two enzyme residues, mainly represented by H-bonds and hydrophobic interactions.CC BY · PubMed Central
Figure 6 Dual AChE/GSK-3β inhibitors 18 and 19 and their relative pharmacophoric elements for the interaction with key enzyme residues.
Figure 6 Dual AChE/GSK-3β inhibitors 18 and 19 and their relative pharmacophoric elements for the interaction with key enzyme residues.CC BY · PubMed Central
Figure 7 Novel ChE/MAO-B dual inhibitors and relative pharmacophoric elements. The new analogues are also endowed with structural elements which confer the ability to chelate metals and to protect against oxidative stress.
Figure 7 Novel ChE/MAO-B dual inhibitors and relative pharmacophoric elements. The new analogues are also endowed with structural elements which confer the ability to chelate metals and to protect against oxidative stress.CC BY · PubMed Central
Figure 8 Structures of dual BuChE/IDO1, ChE/PARP-1, and ChE/PDE inhibitors. While structure 22 is inspired by Miconazole, Olaparib has been taken as the reference structure in the synthesis of MTDL 23, while Donepezil and Rivastigmine, coupled with the pyrazolopyrimidinone structure of a known PDE9A inhibitor led to the identification of compounds with general structures 24 and 25.
Figure 8 Structures of dual BuChE/IDO1, ChE/PARP-1, and ChE/PDE inhibitors. While structure 22 is inspired by Miconazole, Olaparib has been taken as the reference structure in the synthesis of MTDL 23, while Donepezil and Rivastigmine, coupled with the pyrazolopyrimidinone structure of a known PDE9A inhibitor led to the identification of compounds with general structures 24 and 25.CC BY · PubMed Central
Figure 9 The novel THA-adamantanamines 26 and 27 acting as ChE inhibitors and NMDAR antagonists. Also, tacripyrimidines with general structure 28 are here represented as agents influencing Ca2+ influx and intracellular concentration by blocking voltage-gated Ca2+ channels.
Figure 9 The novel THA-adamantanamines 26 and 27 acting as ChE inhibitors and NMDAR antagonists. Also, tacripyrimidines with general structure 28 are here represented as agents influencing Ca2+ influx and intracellular concentration by blocking voltage-gated Ca2+ channels.CC BY · PubMed Central
Figure 10 The discovery of Donecopride (30) inspired by the 5-HT4R agonist RS67333 (29) and the structurally related MTDLs acting as ChE inhibitors and/or serotonin 5-HT4 and 5-HT6 receptor modulators (31 and 32). The general structure 33 has been added as a further modification of the scaffold of RS67333 and Donecopride, although its activity shifted from 5-HTRs to σ1R.
Figure 10 The discovery of Donecopride (30) inspired by the 5-HT4R agonist RS67333 (29) and the structurally related MTDLs acting as ChE inhibitors and/or serotonin 5-HT4 and 5-HT6 receptor modulators (31 and 32). The general structure 33 has been added as a further modification of the scaffold of RS67333 and Donecopride, although its activity shifted from 5-HTRs to σ1R.CC BY · PubMed Central
Figure 11 General structures of recent ChE inhibitors/5-HT6R antagonists. The pharmacophoric elements for the dual activity are highlighted for each structure. Together with the multiple activity, some of these agents are also endowed with antioxidant activity and effects on Aβ aggregation.
Figure 11 General structures of recent ChE inhibitors/5-HT6R antagonists. The pharmacophoric elements for the dual activity are highlighted for each structure. Together with the multiple activity, some of these agents are also endowed with antioxidant activity and effects on Aβ aggregation.CC BY · PubMed Central
Figure 12 General structures of novel combinations for the discovery of dual ChE inhibitors with H3R antagonist (37 and 38) or σ1R agonist (33) activities.
Figure 12 General structures of novel combinations for the discovery of dual ChE inhibitors with H3R antagonist (37 and 38) or σ1R agonist (33) activities.CC BY · PubMed Central
Figure 13 Structures of the novel compounds acting on ChEs (and BACE-1) and able to modulate the ECS via direct interaction with CBRs (40 and 41) or by increasing the ECBs' tone through the inhibition of the AEA-metabolizing enzyme FAAH.
Figure 13 Structures of the novel compounds acting on ChEs (and BACE-1) and able to modulate the ECS via direct interaction with CBRs (40 and 41) or by increasing the ECBs' tone through the inhibition of the AEA-metabolizing enzyme FAAH.CC BY · PubMed Central
Figure 14 Some of the most recent compounds which combine ChE inhibition with the neuroprotective effects, acting on the classical hallmarks of AD, such as Aβ aggregation/disaggregation, metal-induced toxicity, and oxidative stress.
Figure 14 Some of the most recent compounds which combine ChE inhibition with the neuroprotective effects, acting on the classical hallmarks of AD, such as Aβ aggregation/disaggregation, metal-induced toxicity, and oxidative stress.CC BY · PubMed Central
Figure 15 BACE-1 inhibitors with metal-chelating properties and radical scavenging potential.
Figure 15 BACE-1 inhibitors with metal-chelating properties and radical scavenging potential.CC BY · PubMed Central
Figure 16 BACE-1 inhibitors with anti-inflammatory activity related to COX interaction.
Figure 16 BACE-1 inhibitors with anti-inflammatory activity related to COX interaction.CC BY · PubMed Central
Figure 17 General structures of novel MTDLs to treat AD whose actions are not related to their activities on ChEs or BACE-1 enzymes.
Figure 17 General structures of novel MTDLs to treat AD whose actions are not related to their activities on ChEs or BACE-1 enzymes.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 144 references

Cited by

See all 132

Metadata

Authors
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S.
Affiliations
  • University of Siena (IT)
  • Conservatoire National des Arts et Métiers (FR)
  • Stanford Medicine (US)
  • Helmholtz Institute for Pharmaceutical Research Saarland (DE)
Corresponding author
  • Maramai, Samuele
  • Yahiaoui, Samir
Venue
BioMed Research International
Publisher
Wiley
Published
2020-01
Volume
2020
Issue
1
Pages
5120230-5120230
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W3039786831
Cited by
121
References
145
Citations by year
2026: 14 · 2025: 17 · 2024: 20 · 2023: 17 · 2022: 29 · 2021: 22 · 2020: 2
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • HZI (Helmholtz Centre for Infection Research) (submittedVersion, cc-by-nc-sa)
  • Use Siena air (University of Siena) (submittedVersion, cc-by)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, multi-target-directed ligands, multi-target therapy, neurodegeneration, protein aggregation, oxidative stress, neuroinflammation, neuroprotection, metal homeostasis, drug discovery, animal models of dementia
MeSH terms
Alzheimer Disease, Animals, Humans, Ligands, Oxidative Stress, Neuroprotective Agents, Molecular Targeted Therapy, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations. https://app.cochat.ai/papers/10.1155/2020/5120230
The paper
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020). Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations. BioMed Research International. https://doi.org/10.1155/2020/5120230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.